A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Year: 2019
Type: article
Abstract: A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphomaThe treatment landscape for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has evolved from single-agent/combination chemotherapies to anti-CD20 antibody-containing regimens, including chemoimmunotherapy, to novel agents targeting the B-cell receptor signaling pathway or BCL2.In older or less fit patients with comorbidities, standard first-line treatments include chlorambucil combined with anti-CD20 antibodies or single-agent ibrutinib.1 In the CLL11 study, chlorambucil-obinutuzumab showed superior efficacy compared with chlorambucil or chlorambucil-rituximab in patients with previously untreated CLL and comorbidities. 2 Ibrutinib, a first-in-class, once-daily inhibitor of Bruton tyrosine kinase, is approved in the USA and Europe for the treatment of patients with CLL and allows for treatment without chemotherapy.In the ongoing RES-ONATE-2 phase III study (PCYC-1115/1116) in CLL/SLL, single-agent, first-line ibrutinib significantly improved progression-free survival (PFS), overall survival, and overall response rate compared with chlorambucil.3 Recently published results from the iLLUMINATE (PCYC-1130) phase III study showed superior PFS with first-line ibrutinib-obinutuzumab than with chlorambucil-obinutuzumab in patients with CLL/SLL, including patients with high-risk features [del(17p)/TP53 mutation, del(11q), and/or unmutated IGHV].4 Results of additional randomized studies evaluating single-agent ibrutinib versus standard chemoimmunotherapy regimens in first-line CLL were published recently: in the Alliance Intergroup (A041202) phase III trial, it was found that ibrutinib as a single agent or in combination
Source: Haematologica
Authors: Alessandra Tedeschi, Richard Greil, Fatih Demirkan, Tadeusz Robak, Carol Moreno, Paul M. Barr, Bertrand Anz, David Simpson, Gianluca Gaidano, Osnat Bairey, Don Stevens, Devinder Gill, Ian W. Flinn, Thomas J. Kipps, Jan A. Burger, Jennifer Lin, Thomas Webb, Viktor Fedorov, Lori Styles, John G. Gribben
Institutions: Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Paracelsus Medical University, Dokuz Eylül University, Copernicus Memorial Hospital, Medical University of Lodz, Universitat Autònoma de Barcelona, Hospital de Sant Pau, University of Rochester Medicine, University of Rochester, Tennessee Oncology, North Shore Hospital, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Tel Aviv University, Rabin Medical Center, Norton Healthcare, Princess Alexandra Hospital, Sarah Cannon, Moores Cancer Center, The University of Texas MD Anderson Cancer Center, Pharmacyclics (United States), Janssen (United Kingdom), Queen Mary University of London, Barts Cancer Institute
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Funders: Cancer Research Institute, University of Rochester, Tel Aviv University, Uniwersytet Łódzki, Università degli Studi del Piemonte Orientale, Dokuz Eylül Üniversitesi, Universitat de Barcelona, Universitat Autònoma de Barcelona, Paracelsus Medizinische Privatuniversität, Medical Center, University of Rochester, Pharmacyclics, Wilmot Cancer Institute, University of Rochester Medical Center
OpenAlex ID: W2967600517